Azoospermia

Causes include obstructive problems (e.g., vasectomy, congenital absence of the vas deferens, or scarring from infections and pelvic/inguinal surgery) and nonobstructive problems due to testicular failure or impaired hypothalamic–pituitary–gonadal signaling.
Genetic contributors include Klinefelter syndrome (47,XXY), Y‑chromosome microdeletions (AZF regions), and CFTR mutations leading to congenital bilateral absence of the vas deferens.
Environmental and iatrogenic exposures—chemotherapy or radiation, excessive heat (saunas, fevers, varicoceles), pesticides, heavy metals, and organic solvents—can impair spermatogenesis.
Lifestyle and medication factors such as anabolic steroids or exogenous testosterone, chronic opioid or marijuana use, tobacco and heavy alcohol use, obesity, and severe stress increase risk.
Additional risks include undescended testes, mumps orchitis, testicular torsion or trauma, endocrine disorders (pituitary disease, thyroid dysfunction, hyperprolactinemia), chronic systemic illness (e.g., diabetes, kidney disease), and advancing age.

Genetic risk factors

Multiple genetic conditions disrupt sperm production or transport and are frequent contributors to azoospermia. Chromosomal aneuploidies, Y-chromosome microdeletions, and CFTR-related congenital bilateral absence of the vas deferens are the most established causes. Rare single-gene defects and inherited forms of hypogonadotropic hypogonadism also play roles, often with family clustering. Genetic testing for nonobstructive azoospermia can clarify etiology, guide prognosis for sperm retrieval, and inform reproductive counseling.

• Klinefelter syndrome: 47,XXY aneuploidy is a leading chromosomal cause of azoospermia. Primary testicular failure leads to very low or absent sperm with high FSH and LH. Mosaic 46,XY/47,XXY cases may permit rare sperm retrieval.

• Y microdeletions: Deletions in AZFa, AZFb, or AZFc regions cause severe spermatogenic failure. AZFa or AZFb deletions predict almost no chance of testicular sperm, while some AZFc cases allow retrieval. Targeted Y-microdeletion testing is standard in nonobstructive azoospermia.

• CFTR mutations: Biallelic CFTR variants often cause congenital bilateral absence of the vas deferens and obstructive azoospermia. Men may have normal testes but lack the ducts that carry sperm. Partner CFTR testing is recommended to assess cystic fibrosis risk in offspring.

• Chromosomal rearrangements: Balanced translocations or inversions can disrupt meiosis and impair spermatogenesis. Karyotype analysis can identify these structural variants in men with azoospermia. Some rearrangements increase the risk of miscarriage or abnormal embryos.

• Hypogonadotropic hypogonadism genes: Variants in ANOS1, FGFR1, GNRHR, KISS1R, and related genes reduce GnRH signaling. This leads to low LH/FSH and impaired testicular sperm production. Some cases respond to gonadotropin therapy, enabling sperm generation.

• Monogenic spermatogenesis defects: Mutations in TEX11, NR5A1, DMRT1, FANCM and others can cause nonobstructive azoospermia. Gene panels or exome sequencing can identify these defects. Findings can inform prognosis and family counseling.

• Androgen receptor defects: AR gene mutations may cause partial androgen insensitivity with infertility. Phenotypes range from undervirilization to normal male appearance. Testicular biopsy often shows impaired spermatogenesis despite normal hormones.

• SRY and DSD variants: SRY translocation or 46,XX testicular DSD leads to testicular dysfunction and azoospermia. These conditions often show Sertoli-cell-only histology or maturation arrest. Genetic diagnosis clarifies recurrence risk and management.

• Family history patterns: A positive family history suggests inherited risk for spermatogenic failure. Consanguinity increases the likelihood of recessive causes. Pedigree analysis can guide targeted genetic testing.

Transmission

Azoospermia (no sperm in the semen) is not contagious and cannot be transmitted through contact, sex, or any other exposure. It is an individual reproductive condition; while some causes are genetic (such as Y‑chromosome microdeletions, CFTR variants causing absent vas deferens, or chromosomal abnormalities), these can only be inherited by offspring if conception occurs—often via assisted reproduction—and are not “caught” from another person. If a sexually transmitted infection previously damaged the reproductive tract and led to azoospermia, that infection may be transmissible, but azoospermia itself is not. In short, azoospermia has no infectiousness.

When to test your genes

Consider genetic testing if you have confirmed azoospermia, especially nonobstructive azoospermia, before pursuing fertility treatments. Testing (e.g., karyotype, Y-chromosome microdeletions, CFTR) can clarify the cause, guide chances of sperm retrieval, and inform IVF/ICSI planning. It also helps assess hereditary risks and tailor counseling for you and your partner.

Many men with azoospermia can still pursue biological parenthood, but the outlook depends on whether the cause is obstructive (a blockage) or non-obstructive (testicular production problem). Obstructive azoospermia generally has a favorable prognosis: microsurgical reconstruction or sperm retrieval directly from the epididymis/testis combined with in vitro fertilization and intracytoplasmic sperm injection (IVF-ICSI) yields high chances of retrieving usable sperm and achieving pregnancy. Non-obstructive azoospermia has a more variable outlook; success hinges on the extent of intrinsic testicular damage and the presence of focal areas of spermatogenesis that can be found with microdissection testicular sperm extraction (micro-TESE). When sperm are retrievable, IVF-ICSI can lead to live birth rates per cycle that are often comparable to other severe male-factor infertility cases.

If no sperm can be found, donor sperm or adoption remain viable family-building options, and counseling can help with decision-making. Medical treatment may improve outcomes in selected cases: for example, treating hypogonadotropic hypogonadism with gonadotropins can restore spermatogenesis in a substantial proportion of men over months; addressing varicoceles, stopping gonadotoxins, or correcting endocrine disorders may also help. Genetic findings guide prognosis: men with AZFc Y-chromosome microdeletions often have a reasonable chance of sperm retrieval, whereas complete AZFa or AZFb deletions carry a poor prognosis for finding sperm. Because some genetic causes can be passed to offspring through ICSI, preconception genetic counseling is recommended to discuss risks and testing options.

Mortality is not increased by azoospermia itself, but it can signal underlying health issues—such as Klinefelter syndrome, pituitary tumors, or systemic disease—that need evaluation and can carry their own health risks. Early referral to a reproductive urologist improves the likelihood of identifying reversible causes and selecting the most effective treatment pathway. Emotional and financial burdens can be significant; engaging with mental health support and understanding insurance coverage can improve the overall journey. In most cases, the long-tail keyword “outlook for azoospermia” is optimistic when care is individualized, causes are thoroughly investigated, and advanced reproductive technologies are available.

Treatment depends on whether azoospermia is obstructive (sperm made but blocked) or nonobstructive (low/absent sperm production). Obstructive azoospermia is often managed with surgical correction of the blockage (e.g., vasovasostomy for prior vasectomy, transurethral resection for ejaculatory duct obstruction) or sperm retrieval procedures (PESA, MESA, TESA, micro-TESE) combined with IVF/ICSI. Nonobstructive azoospermia is evaluated for reversible causes and treated when present (e.g., stopping gonadotoxins, correcting varicocele, treating infections, weight/thyroid/prolactin optimization), and in select endocrine forms may respond to medical therapy such as gonadotropins or pulsatile GnRH. When focal sperm production exists, micro-TESE with ICSI can enable biological paternity; if no sperm are retrievable or treatment fails, options include donor sperm or adoption. Genetic counseling and testing guide management and reproductive planning, and sperm cryopreservation is recommended when sperm are obtained.

Genetic factors are a major contributor to azoospermia, affecting both sperm production and the development or patency of the reproductive tract. Among chromosomal causes, Klinefelter syndrome (47,XXY) is the most common, and other karyotypic abnormalities or balanced translocations can disrupt spermatogenesis. Microdeletions in the Y‑chromosome AZF regions (AZFa, AZFb, AZFc) are a frequent cause of non‑obstructive azoospermia; AZFa/AZFb deletions predict extremely poor chances of testicular sperm retrieval, whereas AZFc deletions may still allow retrieval but will be transmitted to sons if ICSI is used. For obstructive forms, pathogenic variants in CFTR underlie most cases of congenital bilateral absence of the vas deferens, making paternal CFTR testing and, if positive, partner screening important to assess the risk of cystic fibrosis in children. Gene panels can also reveal single‑gene defects (for example TEX11, NR5A1, and DMRT1) that impair meiosis or testicular development and may influence prognosis. Because these findings guide treatment and reproductive counseling, guidelines recommend karyotype, Y‑microdeletion analysis, and CFTR testing in appropriate azoospermic men, accompanied by genetic counseling.

Azoospermia often coexists with or reveals underlying genetic and endocrine disorders, including Klinefelter syndrome, Y‑chromosome microdeletions, and CFTR mutations that cause congenital bilateral absence of the vas deferens. Pituitary and hypothalamic diseases such as hypogonadotropic hypogonadism, hyperprolactinemia, hemochromatosis, or infiltrative conditions (e.g., sarcoidosis) can suppress gonadotropins and lead to absent sperm production. Prior infections of the testes or reproductive tract—mumps orchitis, tuberculosis, and sexually transmitted infections causing epididymal or vasal scarring—can produce obstructive azoospermia. Severe male factor infertility, including azoospermia, is associated with higher risks of testicular cancer and may occasionally be the first clue to an occult testicular tumor, warranting careful examination and ultrasound when indicated. Chronic systemic illnesses and metabolic disease (obesity, diabetes, chronic kidney or liver disease) can disrupt the hypothalamic–pituitary–gonadal axis and worsen spermatogenic failure. Cancer therapies such as alkylating chemotherapy and pelvic or testicular radiation frequently induce prolonged or permanent azoospermia, making coordination with oncology for fertility preservation crucial.

How genes can cause diseases

Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.

Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.